Other substances

Amodiaquine

An aminoquinoline antimalarial and anti-inflamatory drug.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Used to treat other disease

Supporting references

Contradictory references

AI-suggested references

Clinical trials

General information

Amodiaquine is an aminoquinoline compound with antimalarial and anti-inflammatory activity. It might act through plasmodial heme polymerase inhibition on some Plasmodium strains resistant to chloroquine (NCIt).

Amodiaquine on DrugBank
Amodiaquine on PubChem
Amodiaquine on Wikipedia

Synonyms

Amodiaquine dihydrochloride

CCN(CC)CC1=C(C=CC(=C1)NC2=C3C=CC(=CC3=NC=C2)Cl)O

Supporting references

Link	Tested on	Impact factor	Notes	Publication date
Human organs-on-chips as tools for repurposing approved drugs as potential influenza and COVID19 therapeutics in viral pandemics	human organ-on-a-chip			Apr/14/2020
Antiviral options against SARS-CoV-2 infection Preprint Screening	VERO E6 cell cultures		synergistic effect in combination with the virus-directed drug nelfinavir	May/12/2020
Discovery of Synergistic and Antagonistic Drug Combinations against SARS-CoV-2 In Vitro Preprint In silico	VERO E6 cell cultures		synergistic effect in combination with nitazoxanide, arbidol or lopinavir	Jul/01/2020
Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells: Nafamostat is the most potent antiviral drug candidate Preprint	Calu-3 human airway epithelial cells		higher IC50 value in Calu-3 cells than VERO E6 cells	May/12/2020
Broad anti-coronaviral activity of FDA approved drugs against SARS-CoV-2 in vitro and SARS-CoV in vivo Small molecule Animal model	BALB/c mice; A549 lung adenocarcinoma cells expressing ACE2; Vero E6 cells; SARS-CoV-2 strain MA15	4.32	Inhibits the production of infectious viral particles in vitro and decreases viral gene RNA levels.	Aug/19/2020
Artemisia annua L. extracts inhibit the in vitro replication of SARS-CoV-2 and two of its variants Small molecule In vitro Mixed substance	Vero E6 cells; Calu-3 cells; SARS-CoV-2 isolates USA/WA12020, B1.1.7, and B1.351.	3.69	The compound inhibited SARS-CoV-2 (WT) in Vero E6 cells with an IC50 of 5.8 μM.	Mar/12/2021

AI-suggested references

Link	Publication date
Investigation of Some Antiviral N-Heterocycles as COVID 19 Drug: Molecular Docking and DFT Calculations	May/30/2020
Inhibition of Arenaviruses by Combinations of Orally Available Approved Drugs	Oct/20/2020
Virtual and In Vitro Antiviral Screening Revive Therapeutic Drugs for COVID-19.	Oct/14/2020
Discovery of potential SARS-CoV 3CL protease inhibitors from approved antiviral drugs using: virtual screening, molecular docking, pharmacophore mapping evaluation and dynamics simulation	Sep/20/2021
In silico study indicates antimalarials as direct inhibitors of SARS-CoV-2-RNA dependent RNA polymerase	Mar/07/2022
Synergistic and Antagonistic Drug Combinations against SARS-CoV-2	May/05/2021
Molecular docking and dynamic simulations for antiviral compounds against SARS-CoV-2: A computational study	May/11/2020
Drug repurposing against SARS-CoV-1, SARS-CoV-2 and MERS-CoV	Apr/30/2021
Antimalarial artemisinin-based combination therapies (ACT) and COVID-19 in Africa: In vitro inhibition of SARS-CoV-2 replication by mefloquine-artesunate.	Aug/14/2020
Discovery of re-purposed drugs that slow SARS-CoV-2 replication in human cells	Oct/15/2021
Potential Antiviral Options against SARS-CoV-2 Infection	Nov/05/2020
Broad spectrum anti-coronavirus activity of a series of anti-malaria quinoline analogues.	Jul/01/2021

Clinical trials

ID	Title	Status	Phase	Start date	Completion date
NCT04532931	COVID-19 Treatment in South Africa	Completed	Phase 2	Sep/03/2020	Aug/23/2021
Alternative id - SP-PA-COV-202 Interventions - Other: Standard of care (Paracetamol)\|Drug: Artesunate-amodiaquine\|Drug: Pyronaridine-artesunate\|Drug: Favipiravir plus Nitazoxanide\|Drug: Sofosbuvir/daclatasvir Study type - Interventional Study results - No Results Available Locations - Ezintsha, Wits Reproductive Health & HIV Institute University of the Witwatersrand, Johannesburg, South Africa Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: None (Open Label)\|Primary Purpose: Treatment Enrollment - 192 Age - 18 Years to 65 Years (Adult, Older Adult) Outcome measures - Incidence of SARS-CoV-2 clearance\|Time to clearance of nasal SARS-CoV-2\|Median quantity of SARS-CoV-2\|Proportion of days with fever after randomization\|Proportion of days with respiratory symptoms after randomization\|FLU-PRO© Plus\|Serious adverse events\|Adverse events resulting in treatment discontinuation\|Adverse events considered related to the investigational products\|LRTI\|Maximum score on WHO Ordinal Scale for Clinical Improvement during study participation\|Cumulative incidence of hospitalization\|Days of hospitalization\|Cumulative incidence of mortality

Export (.csv)